Internet Archive Scholar

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

M. S. Gordon, C. J. Sweeney, D. S. Mendelson, S. G. Eckhardt, A. Anderson, D. M. Beaupre, D. Branstetter, T. L. Burgess, A. Coxon, H. Deng, P. Kaplan-Lefko, I. M. Leitch (+4 others)
2010 Clinical Cancer Research  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (723.5 kB)
https://web.archive.org/web/20190219225110/http://pdfs.semanticscholar.org/1c1f/c055e58e273f06c98bc652300157a9b9110d.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

Purpose: The aims were to assess the safety, pharmacokinetics, maximum tolerated dose, and antitumor activity of AMG 102, a fully human hepatocyte growth factor/scatter factor (HGF/SF)-neutralizing monoclonal antibody, in patients with solid tumors. Experimental Design: Patients (N = 40) with refractory advanced solid tumors were enrolled into six sequential dose-escalation cohorts (0.5, 1, 3, 5, 10, or 20 mg/kg AMG 102 i.v. every 2 weeks) and a doseexpansion cohort (20 mg/kg AMG 102 every 2
more » ... ks). Safety, anti-AMG 102 antibody formation, pharmacokinetics, tumor response, and exploratory biomarkers were assessed. Results: AMG 102 was well tolerated up to the planned maximum dose of 20 mg/kg, and the maximum tolerated dose was not reached. Treatment-related adverse events were generally mild and included fatigue (13%), constipation (8%), nausea (8%), vomiting (5%), anorexia (5%), myalgia (5%), and hypertension (5%). Two patients experienced dose-limiting toxicities: one patient (0.5 mg/kg cohort) experienced grade 3 hypoxia and grade 3 dyspnea and one patient (1 mg/kg cohort) experienced grade 3 upper gastrointestinal hemorrhage. No anti-AMG 102 antibodies were detected, and AMG 102 had linear pharmacokinetics within the dose range investigated. Sixteen of 23 (70%) evaluable patients had a best response of stable disease with progression-free survival ranging from 7.9 to 40 weeks. Circulating levels of the biomarker HGF/SF (bound and unbound) increased in a dose-dependent manner, whereas soluble c-Met concentrations were generally similar across doses. Conclusions: AMG 102 is safe and well tolerated, has a favorable pharmacokinetic profile, and will be further investigated as a monotherapy and in combination with other agents.
doi:10.1158/1078-0432.ccr-09-1365 pmid:20068101 fatcat:o6yjj3zrbffdrcvwzvn6bp6bdm
Citation

M. S. Gordon, C. J. Sweeney, D. S. Mendelson, S. G. Eckhardt, A. Anderson, D. M. Beaupre, D. Branstetter, T. L. Burgess, A. Coxon, H. Deng, P. Kaplan-Lefko, I. M. Leitch, K. S. Oliner, L. Yan, M. Zhu, L. Gore. "Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors." Clinical Cancer Research 16.2 (2010) 699-710